Clinical Trial Update: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen [NA]

View source ↗

Summary

A clinical trial evaluated fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in patients with sarcoma receiving ifosfamide-based regimens…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Sarcoma

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Sarcoma, Chemotherapy-induced Nausea and Vomiting | NA | Status: COMPLETED | Results posted: 2015-06-03